BPGAM
ALNY icon

BTG Pactual Global Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

BTG Pactual Global Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,410
Closed -$434K – 68
2018
Q2 		$434K Buy
4,410
+652
+17% +$64.7K 0.13% 52
2018
Q1 		$448K Buy
+3,758
New +$484K 0.12% 58

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BTG Pactual Global Asset Management's ALNY Position: Q3 2018 in Review

BTG Pactual Global Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 4,410 shares — an estimated $434K sold.

BTG Pactual Global Asset Management first reported a position in ALNY in Q1 2018 and held it in 2 quarters. The position peaked at $448K in Q1 2018. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

  • BTG Pactual Global Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 4,410 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $434K.
  • BTG Pactual Global Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • BTG Pactual Global Asset Management's Alnylam Pharmaceuticals position peaked at $448K in Q1 2018.
  • 305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.